

100. (New) The composition of claim 64, wherein the active agent is selected from the group consisting of naproxen, cyclosporine, triamcinolone acetonide, and benzoic acid, 3,5-bis(acetylamino) 2,4,6-triido-, 4-(ethyl-3-ethoxy-2-butenate) ester.

**REMARKS**

Formal examination of this application is respectfully requested.

Claims 98-100 have been added to the application. The claims recite compounds which are disclosed in the examples of the application: naproxen (Examples 1, 2, 3, and 10-15), cyclosporine (Examples 4-6), triamcinolone acetonide (Examples 7 and 8), and benzoic acid, 3,5-bis(acetylamino) 2,4,6-triido-, 4-(ethyl-3-ethoxy-2-butenate) ester (Example 9)..

Because the foregoing amendments do not introduce new matter, entry thereof by the Examiner is respectfully requested.

If the Examiner has any questions concerning this Preliminary Amendment, he or she is requested to contact the undersigned.

Respectfully submitted,

Date May 16, 2002

By Michele M. Simkin

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.